Skip to main content
Fig. 1 | BMC Immunology

Fig. 1

From: CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients

Fig. 1

CD16 expression of peripheral blood myeloid cells were differential in CRC patients after capecitabine therapy. Peripheral venous blood from CRC patients received single-agent oral capecitabine adjuvant therapy was collected before the therapy and 6–9 months after the therapy and analyzed for myeloid cell-related markers. (Attention: Blood were collected 6–9 months after capecitabine treatment unless particularly noted). a Frequencies of CD11b+CD16+myeloid cells were compared before and after capecitabine therapy in capecitabine-sensitive and capecitabine-resistant patients (n = 26 in sensitive group and n = 10 in resistant group, respectively). b Representative images of CD16 expression on CD11b+myeloid cells before and after capecitabine therapy in two CRC patients from capecitabine-sensitive group or capecitabine resistant group, respectively. Diagnosis of drug-resistance was proved by CT scan during the follow-up in Fig. S1e. Mean ± SEM, *P<0.05 by t tests (a)

Back to article page